header logo image

PharmAla Launches MDMA Clinical Trial Tool for Researchers

August 25th, 2024 2:46 am

TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has created a new tool for researchers, providing direct access to its Chemistry, Manufacturing and Control (CMC) data – as well as its investigator’s brochure – to qualified researchers.

Visit link:
PharmAla Launches MDMA Clinical Trial Tool for Researchers

Related Post

Tags:

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick